Statement of Changes in Beneficial Ownership (4)
November 10 2020 - 6:33PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Ignelzi Troy A. |
2. Issuer Name and Ticker or Trading Symbol
Karuna Therapeutics, Inc.
[
KRTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Financial Officer |
(Last)
(First)
(Middle)
C/O KARUNA THERAPEUTICS, INC., 33 ARCH ST STE 3110 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/6/2020 |
(Street)
BOSTON, MA 02110-1424
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/6/2020 | | M | | 564 | A | $9.2 | 5564 | D | |
Common Stock | 11/6/2020 | | S | | 564 | D | $108.15 | 5000 | D | |
Common Stock | 11/9/2020 | | M | | 8000 | A | $9.2 | 13000 | D | |
Common Stock | 11/9/2020 | | S(1) | | 8000 | D | $105.02 | 5000 | D | |
Common Stock | 11/9/2020 | | M | | 1318 | A | $9.2 | 6318 | D | |
Common Stock | 11/9/2020 | | S | | 1318 | D | $108.26 (2) | 5000 | D | |
Common Stock | 11/10/2020 | | M | | 118 | A | $9.2 | 5118 | D | |
Common Stock | 11/10/2020 | | S | | 118 | D | $103.48 | 5000 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Option (right to buy) | $9.20 | 11/6/2020 | | M | | | 564 | 3/1/2020 | 3/21/2029 | Common Stock | 564 | $0 | 235230 | D | |
Option (right to buy) | $9.20 | 11/9/2020 | | M | | | 8000 | 3/1/2020 | 3/21/2029 | Common Stock | 8000 | $0 | 227230 | D | |
Option (right to buy) | $9.20 | 11/9/2020 | | M | | | 1318 | 3/1/2020 | 3/21/2029 | Common Stock | 1318 | $0 | 225912 | D | |
Option (right to buy) | $9.20 | 11/10/2020 | | M | | | 118 | 3/1/2020 | 3/21/2029 | Common Stock | 118 | $0 | 225794 | D | |
Explanation of Responses: |
(1) | The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
(2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.05 to $109.08, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Ignelzi Troy A. C/O KARUNA THERAPEUTICS, INC. 33 ARCH ST STE 3110 BOSTON, MA 02110-1424 |
|
| Chief Financial Officer |
|
Signatures
|
/s/ Troy Ignelzi | | 11/10/2020 |
**Signature of Reporting Person | Date |
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024